Arcus Biosciences (RCUS) Net Margin (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly Net Margin came in at 752.94% in Q1 2026, down 35294.0% year-on-year from N/an in Q1 2025, and down 134.41% quarter-over-quarter from 321.21% in Q4 2025.
Arcus Biosciences (RCUS) Net Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' Net Margin history runs 10 years deep, the most recent figure standing at 752.94% for Q1 2026.
- On a quarterly basis, Net Margin fell 35294.0% year-over-year to 752.94% in Q1 2026; TTM through Mar 2026 was 156.36%, a 12095.0% increase from a year earlier, with the FY2025 full-year figure at 142.91%, down 3323.0% from the prior year.
- Net Margin retreated to 752.94% in Q1 2026 per RCUS's latest filing, from 321.21% in the prior quarter.
- Across five years, Net Margin topped out at 2.76% in Q1 2024 and bottomed at 752.94% in Q1 2026.
- The 5-year median for Net Margin is 289.31% (2023), against an average of 324.18%.
- Across the five-year window, Net Margin surged 62720 bps in 2022 and tumbled 39724 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 197.06% in 2022, then slumped by 194 bps to 578.57% in 2023, then jumped by 38 bps to 361.54% in 2024, then grew by 11 bps to 321.21% in 2025, then tumbled by 134 bps to 752.94% in 2026.
- Per Business Quant, the three latest RCUS Net Margin figures stand at 752.94% (Q1 2026), 321.21% (Q4 2025), and 519.23% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcus Biosciences | 3.73 Bn | 2.90 Bn | - | -752.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -752.94% |
| Dec 31, 2025 | -321.21% |
| Sep 30, 2025 | -519.23% |
| Mar 31, 2025 | -400.00% |
| Dec 31, 2024 | -361.54% |
| Sep 30, 2024 | -191.67% |
| Jun 30, 2024 | -238.46% |
| Mar 31, 2024 | -2.76% |
| Dec 31, 2023 | -578.57% |
| Sep 30, 2023 | -221.88% |
| Jun 30, 2023 | -258.62% |
| Mar 31, 2023 | -320.00% |
| Dec 31, 2022 | -197.06% |
| Sep 30, 2022 | -196.97% |
| Jun 30, 2022 | -248.15% |
| Mar 31, 2022 | -377.78% |
| Dec 31, 2021 | 78.83% |
| Sep 30, 2021 | -824.17% |
| Jun 30, 2021 | -802.98% |
| Mar 31, 2021 | -767.29% |